GABA‐containing compound gammapyrone protects against brain impairments in Alzheimer’s disease model male rats and prevents mitochondrial dysfunction in cell culture

Abstract

Neuroinflammation, oxidative stress, decreased glucose/energy metabolism, and disrupted neurotransmission are changes that occur early in sporadic Alzheimer’s disease (AD), manifesting as mild cognitive impairment. Recently, the imbalanced function of the gamma‐aminobutyric acid (GABA) system was identified as a critical factor in AD progression. Thus, maintaining balance among neurotransmitter systems, particularly the GABA system, can be considered a beneficial strategy to slow AD progression. The present study investigated the effects of the compound gammapyrone, a molecule containing three GABA moieties: “free” moiety attached to the position 4 of the 1,4‐dihydropyridine (DHP) ring, and two “crypto” moieties as part of the DHP scaffold. The “free” and “crypto” GABA moieties are linked by a peptide bond (–CONH–), resulting in a peptide‐mimicking structure. In a nontransgenic male rat AD model generated by intracerebroventricular (icv) streptozocin (STZ) administration, gammapyrone (0.1 and 0.5 mg/kg ip) mitigated the impairment of spatial learning and memory, prevented astroglial and microglial neuroinflammation, and normalized acetylcholine breakdown and GABA biosynthesis. In PC12 cells, gammapyrone protected against oxidative stress, mitochondrial dysfunction and apoptosis caused by the mitochondrial toxin di‐2‐ethylhexyl phthalate (DEHP). Gammapyrone did not bind to GABA‐A and GABA‐B receptors in vitro; therefore, we cannot attribute its neuroprotective action to a specific interaction with GABA receptors. Nevertheless, we suggest that the peptide‐like regulatory mechanisms of gammapyrone or its allosteric modulatory properties are essential for the observed effects. Since, the icv STZ model resembles the early stages of AD, gammapyrone, and/or its congeners could be useful in the design of anti‐dementia drugs.

Healthy Effects of Plant Polyphenols: Molecular Mechanisms

“…A growing number of population surveys and clinical trials increasingly support the use of plant polyphenols, possibly in association with more specific drugs, to prevent and/or to treat several aging-associated pathologies [300]. However, in a number of cases, contradictory results have been reported possibly due to different experimental settings in terms of dose, length of treatment, clinical conditions of the enrolled patients at the onset of treatment, and other unknown variables.…”

Protein Deficiency-Induced Behavioral Abnormalities and Neurotransmitter Loss in Aged Mice Are Ameliorated by Essential Amino Acids

“…With age, the synthesis of these neurotransmitters is known to decline in humans and mice (20)(21)(22)(23). Furthermore, the amount of neurotransmitters, including dopamine, norepinephrine, acetylcholine, Glu, serotonin and GABA, and the levels of their synthetic enzymes are known to be lower in patients with AD than in healthy people (21,24). Dopamine and norepinephrine are monoamines that are associated with cognitive function, particularly working memory (25).…”

Metformin Ameliorates Gestational Diabetes Mellitus-Induced Endothelial Dysfunction via Downregulation of p65 and Upregulation of Nrf2

“…Furthermore, with the progressive shift from a “cure” to “prevention” focus ( Miquel et al., 2018 ; Leri et al., 2020 ), more and more drug research has focused on prevention of diseases and exploration of new functions, such as polyphenols, myopeptides, and GABA-containing compound gammapyrone ( Peters et al., 2018 ; Pilipenko et al., 2019 ; Brunetti et al., 2020 ; Di Rosa et al., 2020 ). In recent years, in addition to glucose lowering effect, several studies have presented evidence showing some potential roles for MET, such as antitumor effect, antiaging effect, cardiovascular protective effect, neuroprotective effect, or an optional treatment for polycystic ovary syndrome ( Wang et al., 2017 ).…”